ESSA PHARMA, INC. HAS BEGUN DEVELOPMENT OF A SECOND GENERATION ANITEN COMPOUND FOR THE TREATMENT OF HORMONE-DRIVEN CANCER

News

News Archives

Date Title

ESSA Pharma Announces Clinical Collaboration with Janssen to Evaluate EPI-7386 Combination for Patients with Metastatic Castration-Resistant Prostate Cancer